Project Grant R43AG079691
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $464,750 to the Icahn School of Medicine at Mount Sinai to conduct research on the genetic determinants of transcription factor binding in pooled microglia samples. The research aims to identify Alzheimer's disease-associated genetic variants that affect the binding of key transcription factors in myeloid cells, such as microglia. The 2-year project will involve performing chromatin...
- This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $4,041,438 to develop new computational tools and biomarkers for Alzheimer's disease. The University of Miami will aggregate and analyze DNA methylation datasets to identify age-associated epigenetic changes related to aging and Alzheimer's progression. Researchers will create a searchable web interface to disseminate findings on the role of DNA...
- This Project Grant award, provided by the National Institute on Aging under CFDA Program 93.866 - Aging Research, supports a $2,516,316 research initiative led by Harvard Medical School to investigate neuronal activity-responsive DNA repair mechanisms and their contribution to cognitive aging and Alzheimer's disease. The key products and services to be delivered under this 3-year grant include: Mapping the landscape of activity-induced DNA double-strand breaks (DSBs) in wild-type mice and...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded $454,937 to Stony Brook University under the Aging Research program (CFDA 93.866) on February 15, 2026, for a project period extending through January 31, 2028. The grant funds research investigating the regulatory landscape of neurodegeneration in Alzheimer's disease (AD) through single-cell spatial multiomics analysis. The project addresses a critical gap in understanding how cells in proximity to AD...
- This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
- This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
- This Project Grant award of $423,994 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University aims to characterize spatial variations in RNA isoform expression in relation to Alzheimer's disease (AD) pathology. The research will leverage single-nucleus cDNA, long-read RNA sequencing, and in situ sequencing to profile isoform expression at single-cell resolution in the inferior frontal gyrus, a brain region pertinent to AD. The study will identify cell-type...
- The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
- Federal Project Grant Award Summary Duke University's Office of Research Administration is conducting a five-year research project funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), with $493,972 obligated for the project period spanning January 1, 2026, through December 31, 2030. The project, titled "Cell Type-Specific Epitranscriptomic Regulation in the Brain in Aging and Alzheimer's Disease," focuses on understanding how adenosine methylation...
SINGLE-CELL EPIGENOME ANALYSIS OF THE ALZHEIMER'S DISEASE BRAIN - TITLE: SINGLE-CELL EPIGENOME ANALYSIS OF THE ALZHEIMER'S DISEASE BRAIN (PI: HARTL) ALZHEIMER'S DISEASE (AD) AFFECTS MORE THAN 6 MILLION AMERICAN BUT NO CURES AND FEW EFFECTIVE TREATMENTS ARE AVAILABLE. GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE UNCOVERED THOUSANDS OF SEGREGATING MUTATIONS THAT SIGNIFICANTLY INCREASE AD RISK. MOST OF THESE VARIANTS ALTER NON-PROTEIN-CODING SEQUENCE AND LACK CLEAR FUNCTIONAL ANNOTATION, HINDERING EFFORTS TO TRANSLATE RISK-CONFERRING MUTATIONS INTO CURATIVE OR PREVENTATIVE THERAPIES. HERITABILITY PARTITIONING SUGGESTS THAT THESE VARIANTS LIKELY PERTURB GENE EXPRESSION IN GLIAL CELLS (ESPECIALLY MICROGLIA), ULTIMATELY LEADING TO AD PATHOLOGY. LINKING THESE VARIANTS - AND THEIR DOWNSTREAM EFFECTS - TO SPECIFIC REGULATORY NETWORKS AND PATHWAYS HAS BEEN HINDERED BY A LACK OF CIS-REGULATORY ELEMENT MAPS FOR THESE MAJOR GLIAL CELL CLASSES AND THEIR SUBTYPES. THE PROPOSED STUDY ADDRESSES THIS CRITICAL KNOWLEDGE GAP BY APPLYING A CUTTING-EDGE SINGLE CELL MULTI-OMIC TECHNOLOGY TO POSTMORTEM HUMAN BRAIN SAMPLES FROM PHENOTYPICALLY NORMAL DONORS AND AD PATIENTS. SPECIFICALLY, THE CHROMATIN ACCESSIBILITY OR HISTONE MODIFICATIONS WILL BE INTERROGATED JOINTLY WITH GENE EXPRESSION AT SINGLE CELL RESOLUTION IN DORSOLATERAL PREFRONTAL CORTEX (DLPFC) FROM MULTIPLE DONORS, TO IDENTIFY AND CHARACTERIZE THE CELL-TYPE-SPECIFIC GENE REGULATORY ELEMENTS THAT DRIVE ABERRANT CELL STATES AND DISEASE-RELEVANT CELLULAR RESPONSES IN HUMAN AD BRAINS. THE SINGLE CELL CHROMATIN STATE AND GENE EXPRESSION ATLASES FROM PHENOTYPICALLY NORMAL INDIVIDUALS WILL BE COMPARED TO THOSE FROM AD SUBJECTS TO DETERMINE THE BRAIN CELL TYPES, GENES AND REGULATORY ELEMENTS THAT EXHIBIT SIGNIFICANT CHANGES IN PATHOLOGICAL CONDITIONS. FINALLY, THE NEWLY GENERATED CELL-TYPE RESOLVED EPIGENOME MAPS WILL BE INTEGRATED WITH PUBLIC GENOMIC RESOURCES TO PROVIDE FUNCTIONAL ANNOTATION OF THE AD RISK VARIANTS, IDENTIFY DISEASE-RELEVANT CELL TYPES, PRIORITIZE GENES, TRANSCRIPTION FACTORS, AND MOLECULAR PATHWAYS FOR FUTURE MECHANISTIC INVESTIGATION. RESULTS OF THE PROPOSED STUDY WILL PROVIDE A MUCH-NEEDED TOOL FOR STUDY OF AD PATHOGENESIS AND DEVELOPMENT OF IMPROVED AD THERAPIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/22/24 | ||
| Not listed | $499.5k | 9/16/22 | ||
| Not listed | $499.5k | 9/16/22 |